Anti-Drug and Anti-Idiotypic Discovery Research
100% success rate across programs to date*
Anti-drug/anti-idiotypic antibody discovery designed for success, delivering reproducible results across diverse formats and assay needs.
The critical link for research
MindWalk delivers what few can claim—a 100% success rate in anti-idiotypic antibody discovery to date.*
Our programs move with speed and rigor, combining scientific expertise with highly trackable, regulatory-facing workflows designed for IND-enabling discovery. With validated assays and reproducible data packages, MindWalk provides the precision and reliability you need as candidates move into downstream development.
* “Success” refers to the generation of anti-idiotypic antibodies meeting predefined analytical criteria across Anti-ID discovery programs. It does not refer to clinical, regulatory, or therapeutic outcomes. Results may vary.
Performance driven
High-affinity and exquisite specificity
Scalable workflows with versatile formats
Customizable solutions
35+ years of experience High client retention
Clear obstacles and reduce bottlenecks
Integrate LensAI™ insights
Fully customizable discovery built to support strong outcomes
A global leader:
Delivering anti-drug discovery and research tool innovation at scale
1,100+ programs completed
Average timeline:
B cell discovery: From immunization to delivery
<12 weeks*
*Timelines may vary depending on program complexity.
Where our research makes a broad impact
Oncology + Infectious Disease + Neurodegeneration + Metabolic Disease + Rare Disease + Inflammation + Market Kits
Anti-drug discovery across complex targets
Antibody discovery + development
Versatile Applications: anti-drug & anti-idiotypic and other research tools (Western Blot, IHC, Flow Cytometry and other applications)
Target
- Target Analysis: Experience-based Antigen Design
- Tool Generation: Custom Antigen Production, Assay Development
Discovery
- Immunization: Standard, Rapid, Custom
- Hit Generation & Candidate Selection: B cell Discovery, Hybridoma Discovery
Lead
- Lead Characterization: Target Interaction Analysis
- LensAI HYFT Prime™: Binding Affinity Optimization, Target Specificity and Selectivity
- Target- and Application-specific Screening
- Protein Production: Recombinant Protein Expression in CHO, HEK293, E.coli
Stable Production Cell Line
Functional Selection
- Epitope Mapping
- Affinity
- Specificity
- Competing/Non-competing
- Pairing Identification
- Application-relevant Screening
Species Diversity
+ Rabbit
+ Rodent
Advanced Technology
+ B cell Select®
+ Hybridoma
Format Options
- Full-length IgG
- Custom Formats
Additional discovery innovation
Veterinary medicine, diagnostics and science
Used by teams across 19 of the top 20 global pharma companies, next-generation biotechs, and leading research institutions
An extension of
your team.
#1 ranking lab*
*ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Take the first step
Let’s expand what’s possible for human health.
Four ways to access MindWalk
We build it
Customizable offerings in biologics discovery—from target analysis to optimized leads.
You build it
Access to state-of-the-art LensAI SaaS Platform.
The Vault
Smarter starts: a portfolio of partner-ready assets.
Partnership
We are proud to partner with the best in pharma, biotech and academia organizations. Join us in creating future of human health.